In a video interview with Healio, Benjamin N. Ungar, MD, discussed the risk factors of atopic dermatitis and the comorbidities associated with the condition.

Several studies show that a measles infection can suppress the immune system for up to three years, making people susceptible ...

Q4 2024 Earnings Call Transcript March 27, 2025 STRATA Skin Sciences, Inc. misses on earnings expectations. Reported EPS is $ ...

Robert Sidbury MD, MPH explored the “long list” of treatment options in atopic dermatitis and how the treatment landscape has changed as a result in a video interview with Healio.“So long list – I ...

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

This compares with around 10% to 30% of children. With “atopic march,” a person initially has atopic dermatitis, and they later develop other atopic conditions such as allergic rhinitis ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a ...

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...